TOP HEADLINES

Featured Story

  • Tufts survey shows social media still on fringes of clinical trials

    It is almost four years since Facebook passed 500 million users. And while the role of it and other social media in clinical trials has generated lots of media coverage and conference chatter, the industry is yet to fully embrace the tools. Survey data published this week show just how there is to go.

Wellcome Trust order helps Illumina blast past HiSeq X Ten sale forecasts

When Illumina unveiled its $1,000 genome machine, there were a few doubts about how many organizations had a big enough sequencing pipeline to justify buying the equipment. Now a purchase by the Wellcome Trust Sanger Institute has taken Illumina's order book up to 104 machines, almost double its original forecast.

NIH lays out plan to work exome data into clinical research

Having seen the cost of exome sequencing tumble in recent years, the U.S. National Institutes of Health has decided now is the time to jump-start its genomic medicine program. The upshot is more clinical research programs will soon have access to exome sequencing capabilities and NIH support with management of the resulting data.

Philippines opens IBM-powered bioinformatics facility

PGC set up the bioinformatics center to complement its existing next-generation sequencing work.

Google adds UCSF geneticist to Calico's roster

In the months since details of Google's Calico last leaked into the public domain, the creation of a new J. Craig Venter company has further increased interest in anti-aging. And while Calico has been out of the headlines, it has continued to build out its anti-aging dream team, with a UCSF geneticist the latest to join.

Pfizer, PhRMA and others pick holes in FDA social media guidance

Drugmakers received the first slice of FDA social media guidance in January, and now the FDA's mailbag is filling up with letters on First Amendment protections, "jurisdictional creep" and other topics from the likes of Pfizer and PhRMA.

MORE NEWS

From Our Sister Sites

FierceCRO

Going well beyond the standard sponsor-CRO relationship, Biogen Idec has recruited Quintiles to revamp its clinical development process, giving the contractor a seat at the R&D table to improve trial efficiency.

FiercePharma

With a host of biologic products in its pipeline, Bristol-Myers Squibb sees the need for more capacity for making large-molecule drugs and has decided to build on a relationship it already has with South Korea's Samsung BioLogics.